XML 32 R18.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT REPORTING
 3 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING

NOTE 9 — SEGMENT REPORTING

 

For the period ending September 30, 2025, the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately because they require different technology and marketing strategies.

 

Reportable Segment   Description
RENB   Developing new immunotherapies to combat cancer
BioSymetrics   Integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine.
RENC   Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection

 

The Company’s chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly. During the period ending September 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The accounting policies of each segment are the same as those described in the summary of significant accounting policies.

 

On September 2, 2025, the Court of Amsterdam (the “Court”) declared bankrupt Gedi Cube B.V. (“Gedi”), an indirect subsidiary of Lunai Bioworks, Inc. (“Lunai”), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary petition seeking a declaration of bankruptcy due to its inability to make payments as they became due. As a result of this, the Company deconsolidated Gedi Cube B.V. due to the loss of control of the subsidiary during the period ended September 30, 2025. As a result of the deconsolidation, the Company recognized a gain on the bankruptcy of the subsidiary for $12,019,227 during the period ended September 30, 2025.

 

               
    Operating loss   Assets
United States (RENB)   $ 2,700,505     $ 867,678  
United States (BioSymetrics)     273,951       6,092,985  
Netherlands (RENC)     333,904       —  
    $ 3,308,360     $ 6,960,663  

 

The chief operating decision maker uses loss from operations to evaluate the performance of each segment’s assets in deciding how to allocate available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by benchmarking the Company’s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing the performance of the segment.

 

Information regarding each reportable segment for the three months ended September 30, 2025, is as follows:

 

                               
    RENB   BioSymetrics   RENC   Total
General and administrative   $ 1,822,729     $ 253,883     $ 333,904     $ 2,410,516  
Research and development     20,419       3,988       —       24,407  
Long-lived asset impairment     831,915       —       —       831,915  
Depreciation and amortization     25,442       16,080       —       41,522  
                                 
Segment operating loss   $ 2,700,505     $ 273,951     $ 333,904       3,308,360  

 

Geographic information:

 

RENB, BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively. The geographic information analyses the Company’s operations and assets based on the country in which each segment operates. In presenting this geographic information, segment operating results have been based on the geographic location in which the services were provided to the segment and segment assets were based on the geographic location of the assets.